切换至 "中华医学电子期刊资源库"
高级检索
中华危重症医学杂志(电子版)

中华危重症医学杂志(电子版) ›› 2018, Vol. 11 ›› Issue (04) : 265 -269. doi: 10.3877/cma.j.issn.1674-6880.2018.04.010

所属专题： 文献；

荟萃分析

白细胞介素12B rs3212227基因多态性与肝细胞癌发生相关性的Meta分析
周卫江1,†(), 陆军1, 万亚锋1   
  1. 1. 310006　杭州，浙江大学医学院附属杭州市第一人民医院肝胆胰外科
  • 收稿日期:2018-06-10 出版日期:2018-08-01
  • 通信作者: 周卫江

Meta-analysis of the association between interleukin-12B rs3212227 polymorphism and hepatocellular carcinoma

Weijiang Zhou1,†(), Jun Lu1, Yafeng Wan1   

  1. 1. Department of Hepatobiliary and Pancreatic Surgery, Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China
  • Received:2018-06-10 Published:2018-08-01
  • Corresponding author: Weijiang Zhou
  • About author:
    Corresponding author: Zhou Weijiang, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

周卫江, 陆军, 万亚锋. 白细胞介素12B rs3212227基因多态性与肝细胞癌发生相关性的Meta分析[J]. 中华危重症医学杂志(电子版), 2018, 11(04): 265-269.

Weijiang Zhou, Jun Lu, Yafeng Wan. Meta-analysis of the association between interleukin-12B rs3212227 polymorphism and hepatocellular carcinoma[J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2018, 11(04): 265-269.

目的

系统评价白细胞介素12B（IL-12B）rs3212227基因多态性与肝细胞癌发病风险的相关性。

方法

计算机检索CNKI、万方、维普、Pubmed、Medline及OVID等数据库，纳入含有IL-12B rs3212227多态性与肝细胞癌相关性信息的文献。由2位研究者按照纳入标准进行文献筛选及数据提取，使用STATA 14.0软件进行Meta分析，并采用Eggr's检验识别发表偏倚。

结果

共纳入8篇研究，在共显性模型（AC vs. AA）中，IL-12B rs3212227基因多态性与肝细胞癌无明显相关性（Z= 1.84，P= 0.065），而在等位基因模型（C vs. A）、显性模型（CC+ AC vs. AA）、隐性模型（CC vs. AC+ AA）及共显性模型（CC vs. AA）中，C基因型可增加肝细胞癌的发病风险（Z= 2.90，P= 0.004；Z= 3.12，P= 0.002；Z= 2.26，P= 0.024；Z= 2.92，P= 0.003）。分层分析中，以随机人群为来源的研究，在显性模型（CC+ AC vs. AA）中，IL-12B rs3212227基因多态性与肝细胞癌存在相关性[OR= 1.17，95%CI（1.01，1.35），Z= 2.04，P= 0.041]，以医院人群为来源的研究，除共显性模型（AC vs. AA）外[OR= 1.12，95%CI（0.93，1.36），Z= 1.22，P= 0.222]，而等位基因模型（C vs. A）[OR= 1.16，95%CI（1.03，1.30），Z= 2.54，P= 0.011]、显性模型（CC+ AC vs. AA）[OR= 1.22，95%CI（1.04，1.43），Z= 2.39，P= 0.017]，隐性模型（CC vs. AC+ AA）[OR= 1.25，95%CI（1.03，1.53），Z= 2.26，P= 0.024]和共显性模型（CC vs. AA）[OR= 1.37，95%CI（1.09，1.73），Z= 2.69，P= 0.007]模型与肝细胞癌存在相关性。

结论

IL-12B rs3212227基因多态性与肝细胞癌存在相关性，C基因型可增加肝细胞癌的发病风险。

关键词: 癌，肝细胞, 白细胞介素12, 基因多态性, Meta分析
Objective

To systemically explore the association between interleukin 12B (IL-12B) rs3212227 polymorphism and risk of hepatocellular carcinoma.

Method

Systematic searches were conducted in CNKI, Wanfang data, VIP, PubMed, Medline and OVID to collect the articles with relevant information of IL-12B rs3212227 polymorphism and hepatocellular carcinoma. Two reviewers independently screened articles and extracted data according to the inclusion criteria. The STATA 14.0 software was used to perform Meta analysis. The Eggr's test was applied to evaluate the publication bias.

Results

A total of 8 studies were included. In the co-dominant model (AC vs. AA), IL-12B rs3212227 polymorphism was not associated with hepatocellular carcinoma (Z= 1.84, P= 0.065), while in allele model (C vs. A), dominant model (CC+ AC vs. AA), implicit model (CC vs. AC+ AA) and co-dominant model (CC vs. AA), C genotype increased the risk of hepatocellular carcinoma (Z= 2.90, P= 0.004; Z= 3.12, P= 0.002; Z= 2.26, P= 0.024; Z= 2.92, P= 0.003). For the stratified analysis, in the population-based study, IL-12B rs3212227 polymorphism was associated with hepatocellular carcinoma in the dominant model (CC+ AC vs. AA)[OR= 1.17, 95%CI(1.01, 1.35), Z= 2.04, P= 0.041], and in the hospital-based study, IL-12B rs3212227 polymorphism was associated with hepatocellular carcinoma in allele model (C vs. A)[OR= 1.16, 95%CI(1.03, 1.30), Z= 2.54, P= 0.011], dominant model (CC+ AC vs. AA)[OR= 1.22, 95%CI (1.04, 1.43), Z= 2.39, P= 0.017], implicit model (CC vs. AC+ AA)[OR= 1.25, 95%CI (1.03, 1.53), Z= 2.26, P= 0.024] and co-dominant model (CC vs. AA)[OR= 1.37, 95%CI (1.09, 1.73), Z= 2.69, P= 0.007], except for the co-dominant model (AC vs. AA)[OR= 1.12, 95%CI (0.93, 1.36), Z= 1.22, P= 0.222].

Conclusion

IL-12B rs3212227 polymorphism is associated with hepatocellular carcinoma and the C genotype can increase the hepatocellular carcinoma risk.

Key words: Carcinoma, hepatocellular, Interleukin-12, Polymorphism, Meta-analysis
表1 病例组和对照组中IL-12B rs3212227基因的分布
第一作者 种族 对照来源 病例组 对照组 HWE
AA AC CC AA AC CC
Nieters等[14] 亚洲人 医院人群 56 NA NA 72 NA NA -
Ognjanovic等[15] 高加索人 随机人群 57 NA NA 128 NA NA -
刘莉等[16] 亚洲人 随机人群 162 271 100 169 259 86 0.43
Liu等[17] 亚洲人 随机人群 249 422 160 272 414 158 0.98
杨艳等[18] 亚洲人 医院人群 156 309 143 195 302 115 0.92
Saxena等[19] 亚洲人 随机人群 19 31 9 63 71 14 0.35
Tan等[20] 亚洲人 医院人群 104 201 90 200 347 139 0.61
Elsayed等[21] 非洲人 医院人群 41 22 15 38 40 14 0.52
图1 白细胞介素12B rs3212227基因多态性与肝细胞癌相关性的森林图
1
Ghouri YA,Mian I,Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis[J]. J Carcinog, 2017, 16(1): 1-8.
2
Torre LA,Bray F,Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
3
Alswat KA,Sanai FM,Altuwaijri M, et al. Clnical characteristics of patients with hepatocellular carcinoma in a middle eastern population[J]. Hepat Mon, 2013, 13(5): e7612.
4
Shao YY,Lu LC,Lin ZZ, et al. Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems[J]. Br J Cancer, 2012, 107(10): 1672-1677.
5
Borzio M,Fornari F,De SI, et al. Adherence to American Association for the Study of Liver Diseases guidelines for the management for hepatocellular carcinoma: results of an Italian field practice multicenter study[J]. Fut Oncol, 2013, 9(2): 283-294.
6
Gavriilides P,Askari A,Azoulay D. Survival following redo hepatectomy vs radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis[J]. HPB (Oxford), 2017, 19(1): 3-9.
7
Vignali DA,Kuchroo VK. IL-12 family cytokines: immunological playmakers[J]. Nat Immunol, 2012, 13(8): 722-728.
8
Tan SM,Kapp M,Flechsig C, et al. Stimulating surface molecules, Th1-polarizing cytokines, proven trafficking-a new protocol for the generation of clinical-grade dendritic cells[J]. Cytotherapy, 2013, 15(4): 492-506.
9
Carpi A,Nicolini A,Antonelli A, et al. Cytokines in the management of high risk or advanced breast cancer: an update and expectation[J]. Curr Cancer Drug Targets, 2009, 9(8): 888-903.
10
Seki S,Nakashima H,Nakashima M, et al. Antitumor immunity produced by the liver Kupffer cells, NK cells, NKT cells, and CD8 CD122 T cells[J]. Clin Dev Immunol, 2011 (2011): 868345.
11
Marcais A,Viel S,Grau M, et al. Regulation of mouse NK cell development and function by cytokines[J]. Front Immunol, 2013 (4): 450.
12
Huang D,Cancilla MR,Morahan G. Complete primary structure, chromosomal localization, and definition of polymorphisms of the gene encoding the human interleukin-12 p40 subunit[J]. Genes Immun, 2000, 1(18): 515-520.
13
Hall MA,McGlinn E,Goakley G, et al. Genetic polymorphism of IL-12 p40 gene in immune-mediated disease[J]. Genes Immun, 2000, 1(3): 219-224.
14
Nieters A,Yuan JM,Sun CL, et al. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association[J]. Cancer, 2005, 103(4): 740-748.
15
Ognjanovic S,Yuan JM,Chaptman AK, et al. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA[J]. Carcinogenesis, 2009, 30(5): 758-762.
16
刘莉,刘政,徐研, 等. IL12基因多态性与原发性肝细胞肝癌遗传易感性的关联研究[J]. 南京医科大学学报（自然科学版）, 2010, 30(1)：34-38.
17
Liu L,Xu Y,Liu Z, et al. IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population[J]. Int J Cancer, 2011, 128(7): 1692-1696.
18
杨艳,仇小强,余红平, 等. 广西肝细胞癌与TGF-β1及IL-12B基因多态性关系[J]. 中国公共卫生, 2011, 27(11)：1383-1385.
19
Saxena R,Chawla YK,Verma I, et al. Effect of IL-12B, IL-2, TGF-β1, and IL-4 polymorphism and expression on hepatitis B progression[J]. J Interferon Cytokine Res, 2014, 34(2): 117-128.
20
Tan A,Gao Y,Yao Z, et al. Genetic variants in IL12 influence both hepatitis B virus clearance and HBV-related hepatocellular carcinoma development in a Chinese male population[J]. Tumour Biol, 2016, 37(5): 6343-6348.
21
Elsayed HM,Nabiel Y,Sheta T. IL-12 gene polymorphism in association with hepatocellular carcinoma in HCV-infected Egyptian pastients[J]. Immunol Invest, 2017, 46(2): 123-133.
22
Desantis CE,Lin CC,Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014[J]. CA Cancer J Clin, 2012, 62(4): 252-271.
23
Li J,Ju Y. Association between the functional polymorphism of vascular endothelial growth factor gene and breast cancer: a meta-analysis[J]. Iran J Med Sci, 2015, 40(1): 2-12.
24
Wang J,Nong L,Wei Y, et al. Association of interleukin-12 polymorphisms and serum IL-12p40 levels with osteosarcoma risk[J]. DNA Cell Biol, 2013, 32(10): 606-610.
[1] 张思平, 刘伟, 马鹏程. 全膝关节置换术后下肢轻度内翻对线对疗效的影响[J]. 中华关节外科杂志(电子版), 2023, 17(06): 808-817.
[2] 罗旺林, 杨传军, 许国星, 俞建国, 孙伟东, 颜文娟, 冯志. 开放性楔形胫骨高位截骨术不同植入材料的Meta分析[J]. 中华关节外科杂志(电子版), 2023, 17(06): 818-826.
[3] 李雄雄, 周灿, 徐婷, 任予, 尚进. 初诊导管原位癌伴微浸润腋窝淋巴结转移率的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 466-474.
[4] 莫闲, 杨闯. 肝硬化患者并发门静脉血栓危险因素的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 678-683.
[5] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[6] 张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[7] 严庆, 刘颖, 邓斐文, 陈焕伟. 微血管侵犯对肝癌肝移植患者生存预后的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 624-629.
[8] 段文忠, 白延霞, 徐文亭, 祁虹霞, 吕志坚. 七氟烷和丙泊酚在肝切除术中麻醉效果比较Meta分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 640-645.
[9] 张文华, 陶焠, 胡添松. 不同部位外生型肝癌临床病理特点及其对术后肝内复发和预后影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 651-655.
[10] 韩宇, 张武, 李安琪, 陈文颖, 谢斯栋. MRI肝脏影像报告和数据系统对非肝硬化乙肝患者肝细胞癌的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 669-673.
[11] 张维志, 刘连新. 基于生物信息学分析IPO7在肝癌中的表达及意义[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 694-701.
[12] 陈安, 冯娟, 杨振宇, 杜锡林, 柏强善, 阴继凯, 臧莉, 鲁建国. 基于生物信息学分析CCN4在肝细胞癌中表达及其临床意义[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 702-707.
[13] 叶文涛, 吴忠均, 廖锐. 癌旁组织ALOX15表达与肝癌根治性切除术后预后的关系[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 708-712.
[14] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[15] 杜锡林, 谭凯, 贺小军, 白亮亮, 赵瑶瑶. 肝细胞癌转化治疗方式[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 597-601.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号